)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Bio-Path
Bio-Path (BPTH) investor relations material
Bio-Path Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary20 May, 2026
Executive summary
Focused on RNAi nanoparticle drug development for oncology and obesity, with four drug candidates in development targeting cancer and metabolic diseases.
Lead candidate prexigebersen is in a Phase 2 trial for AML, with promising interim results; other candidates target Bcl-2, STAT3, and obesity-related pathways.
Operations paused and most employees furloughed as of June 2025 due to capital constraints; seeking additional financing and strategic partnerships.
Financial highlights
Net loss for Q1 2026 was $0.3 million, a significant decrease from $2.9 million in Q1 2025, driven by reduced R&D and G&A expenses.
Cash balance at March 31, 2026 was $0.1 million, up slightly from year-end 2025, but insufficient for 12 months of operations.
Stockholders’ deficit increased to $(8.5) million as of March 31, 2026.
No revenue generated in Q1 2026.
Outlook and guidance
Expects to continue incurring significant operating losses and require substantial additional capital for ongoing and future clinical trials.
Future operations depend on successful fundraising, licensing, or partnership agreements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bio-Path
- Q2 net loss narrowed, cash rose, clinical pipeline advanced, but liquidity risks remain.BPTH
Q2 20241 Feb 2026 - Strong AML remission rates and pipeline progress showcased, supported by robust IP and cash.BPTHH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Pipeline expanded beyond oncology; Q3 loss narrowed, but cash and Nasdaq risks remain.BPTHQ3 202413 Jan 2026
- Operational pause, depleted cash, and debt defaults highlight urgent need for new funding.BPTHQ3 202513 Jan 2026
- Registering 17.8M shares for resale from recent warrants, with proceeds for working capital if exercised.BPTHRegistration Filing16 Dec 2025
- Registering 5.57M shares for resale, with future warrant proceeds to fund operations.BPTHRegistration Filing16 Dec 2025
- Key votes include director elections, auditor ratification, stock plan amendment, and reverse split.BPTHProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, stock plan, reverse split, and private placement.BPTHProxy Filing2 Dec 2025
- Key votes include director elections, auditor ratification, stock plan amendment, and reverse split.BPTHProxy Filing2 Dec 2025
Next Bio-Path earnings date
Q4 202519 Jun, 2026
Bio-Path
Next Bio-Path earnings date
Q4 202519 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage